ArticleScientific reports2025
The global burden of breast cancer among women of reproductive age: a comprehensive analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Financial toxicity among patients with breast cancer: a systematic review and meta-analysis.The oncologist · 2026Pooled it
- Young Women Diagnosed With Breast Cancer: Why Is No One Telling Me to Get a Mammogram?Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2026Article
- Review
- Structure-Function Regulation of Proteolytically Stable Amphiphilic Peptide-Based Soft Materials With Antimicrobial Efficacy Against Drug-Resistant Strains and Anticancer Activity in Triple-Negative Breast Cancer Cells.Chembiochem : a European journal of chemical biology · 2026Article
- A Rationally Engineered Norfloxacin-Phenoxazine Hybrid as a Dual-Function Anticancer Agent: DNA Intercalation Synergizes with Topoisomerase II Inhibition against Murine Breast Tumor.ACS medicinal chemistry letters · 2026Article
- The Non-Coding rs5945619 Variant at Xp11.22 and Its Putative Regulatory Effects on Nearby Genes in Ecuadorian Mestizo Women with Breast Cancer: A Case Series and In Silico Cis-eQTL Analysis.International journal of molecular sciences · 2026Article
- Health related quality of life of patients with breast cancer in Malaysia: evidence from EQ-5D-5L and EORTC QLQ-C30.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Cardiac Modulation byCurrent issues in molecular biology · 2026Article
- Breast cancer survival prediction using machine learning and multimodal data for personalized care plan.BMC cancer · 2026Article
- Association Between Coffee and Caffeine Intake and Risk of Breast Cancer: A Systematic Review and Meta-Analysis of Cohort Studies.Health science reports · 2026Review
- Global burden of breast cancer and its association with red meat consumption: spatiotemporal trends, projections, and triangulation of evidence.World journal of surgical oncology · 2026Article
- PCOS and breast cancer risk: hormonal modulation and epidemiological trends.Reproductive health · 2026Review
- Metabolic Syndrome Is Associated with Increased Plasma Fibroblast Growth Factor 21 (FGF21) in Postmenopausal Breast Cancer Survivors: Implications for Therapy and Diagnosis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Functional analysis of a splicing variant of the DOCK8 gene in a patient with breast cancer (Buryat ethnicity).Asian Pacific journal of cancer prevention : APJCP · 2026Article
- DCBLD1 as a novel prognostic biomarker and therapeutic target in breast cancer: clinical validation and mechanistic insights.Annals of medicine and surgery (2012) · 2026Article
- Evaluation of a National Breast Cancer Screening Program in a Middle-Income Country: The Case of Kazakhstan.International journal of environmental research and public health · 2026Article
- Breast cancer burden among women of reproductive age in China, Japan, and South Korea, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.International journal of clinical oncology · 2026Article
- Integrative immunogenomic and experimental characterization reveals CXCL9, CXCL13, CCL5 and CD74 as key oncogenic drivers in breast cancer.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- The global burden of early-onset cancer in women, 1990-2021: findings from the GBD 2021 with focus on China.Journal of the National Cancer Center · 2026Article
- The Burden of Breast Cancer and its Attributable Risk Factors in 204 Countries and Territories, 1990-2021: Results From the Global Burden of Disease Study 2021.Cancer innovation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most prevalent malignant disease among women and affects women of reproductive age (15-49 years) across the globe. This study examines patterns and trends in the epidemiology of breast cancer in women of reproductive age using global burden of disease data (1990-2021), with the objective of informing targeted public health strategies. Using data from the Global Burden of Disease Study (GBD 2021), this study analyzed the temporal trends, regional disparities, and health inequalities in the burden of breast cancer among women of reproductive age across 204 countries and territories from 1990 to 2021. The analysis employed methodologies including the age-period-cohort (APC) model, decomposition analysis, the slope index of inequality (SII), and the concentration index (CIX). Additionally, the Bayesian age-period-cohort (BAPC) predictive model was utilized to forecast the global burden of breast cancer among women of reproductive age from 2022 to 2040. From 1990 to 2021, the global burden of breast cancer among women of reproductive age showed a significant upward trend, with increases of 118.7%, 121.3%, and 66.8% in the number of new cases, prevalence, and disability-adjusted life years (DALYs) lost, respectively. The most pronounced increases were observed in regions with low and low-middle sociodemographic index (SDI). APC analysis revealed that the rising incidence and prevalence rates were driven by age and period effects, while the risk of breast cancer declined among more recent birth cohorts. Decomposition analysis indicated that population aging and growth were the primary contributors to the global rise in breast cancer burden. SII and CIX analyses demonstrated that absolute health inequalities in breast cancer burden intensified during this period, while relative inequalities showed a slight decline. According to the BAPC predictive model, by 2040, the number of new breast cancer cases among women of reproductive age is expected to increase by 47.8% compared to 2022, accompanied by continued rises in age-standardized incidence, prevalence, and mortality rates. Between 1990 and 2021, the global burden of breast cancer among women of reproductive age increased significantly, with notable health inequalities across regions and populations. By 2040, new cases are projected to rise by 47.8% from 2022, underscoring an urgent global challenge in breast cancer prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.